The interaction of platelet-related factors with tumor cells promotes tumor metastasis

Table 1 Drug targeting platelet-related factors in the lung, breast and colorectal cancer

Cancer name	Platelet-related factor	Targeted drug	Drug trial phase	Refs
Lung cancer	PD-L1	Medi4736	Clinical Phase	[178]
	P-selection	LMWH	Clinical Phase	[110, 179, 180]
	Integrin αIIbβ3	Abciximab	Clinical Phase	[184]
	Integrin αvβ3	Cilengitide MRL-123	Clinical Phase III	[185]
	ATX	GLPG1690	Clinical Phase	[191, 193]
	VEGF	Bevacizumab	Approval	[186]
	bFGF	PD173074	In vitro and in vivo	[189]
Breast cancer	PD-L1	Medi4736	Clinical Phase	[178]
	P-selection	LMWH	Clinical Phase	[110, 179, 180]
	LPA	LPA monoclonal antibodies	Clinical Phase I	[190]
	ATX	GLPG1690	Clinical Phase	[191, 192]
	Integrin αvβ3	Cilengitide MRL-123	Clinical Phase III	[185]
	VEGF	Bevacizumab	Approval	[138]
	bFGF	PD173074	In vitro and in vivo	[189]
Colorectal cancer	PDGF	6B3, MOR8457, Compound P2	Clinical Phase	[195,196,197]
	GPVI	Glenzocimab	Clinical Phase	[188]
	ATX	GLPG1690	Clinical Phase	[191]
	VEGF	Bevacizumab	Approval	[187]
	bFGF	PD173074	In vitro and in vivo	[189]

ISSN: 1479-5876